To provide a method for simply judging an ATL onset in early stages, a diagnostic for an ATL onset and its therapeutic agent or prophylactic.
It is determined that a subject is a HTLV-1 infected patient and/or ATL patient by using reduction of expression level of NDRG2 in a subject-derived cell as an index when the expression level of NDRG2 in the subject-derived cell is compared with the expression level of NDRG2 in a control cell. Otherwise, it is determined that a subject is a HTLV-1 infected patient and/or ATL patient by using much methylation of an NDRG2 promoter in a subject-derived cell as an index when the methylation is measured. The ATL diagnostic comprises an antibody against an NDRG2 protein. The medicine for preventing and/or treating ATL comprises an NDRG2 gene or an NDRG2 protein as an active ingredient.
COPYRIGHT: (C)2009,JPO&INPIT
Masashi Taniwaki
Hama Saki Makoto
Miyazaki Prefecture Industrial Support Foundation